Daryl L. Thompson is an American inventor, entrepreneur, and biohacker known for his contributions to pharmaceutical and biological research through published papers, [1] [2] works cited in the scientific community, [3] and multiple US patents. [4] Thompson's research focuses on the development of innovative therapeutic platforms for a wide range of applications, including metabolic, neurologic, cancer, and infectious diseases.
Since 2010, Thompson has served as President and Director of Scientific Initiatives at Global Research and Discovery Group (GRDG Sciences, LLC) in Winter Haven, FL, which is a private research and development organization. GRDG Sciences is a think tank that works to provide solutions to emerging global epidemics and pandemics. [5]
Thompson and GRDG have completed a 5-year comprehensive research project of highly valued biodefense applications. GRDG and Thompson are now focused on licensing their portfolio to larger pharmaceutical companies for down range development. [6]
Thompson's company GRDG works outside of government institutions and is exclusively focused on developing medical countermeasures that adhere to the principles and initiatives established by Project Bioshield, BARDA, and the Potomac Institute for Policy Studies.
Thompson is Director of Scientific Initiatives and a member of the Board of Directors of Interceptor Therapeutics, a partnership formed to develop and commercialize Daryl's technology. Interceptor Therapeutics includes former Assistant Surgeon General of the United States Dr. Roscoe M. Moore, Jr. as Senior Scientific Adviser.
Thompson was previously President of ATM Metabolics, LLC which specializes in the development of phyto-chemical pharmaceuticals aimed at preventing and reversing metabolic and neurological diseases.
Thompson was a founder, partner, and served as senior vice president and director of research at Solution Health Systems, Boca Raton, FL, from 2003 to 2006. During that time, his research focused on metabolic issues to solve the global diabetes epidemic.
In 2000, Thompson was recognized for designing a non-invasive glucose meter and received the Diabetes World Humanitarian Award from the Diabetes Research Center.
Thompson is co-author of three published scientific studies:
An upcoming documentary focused on engaging science-based adventure and educational nexus. The Bioquest follows the research team of GRDG as they explore unique locations around the world sharing exciting stories behind their biomedical discoveries focused on solutions to global health issues. This research is presented in a way that is both educational and entertaining. [9]
Daryl Thompson and GRDG are focused on licensing their technology portfolio to larger pharmaceutical companies and that process is underway. GRDG and Thompson have successfully introduced and coordinated the licenses of the Linebacker and Equivir technologies with Prophase laboratories.
A multi-faceted therapeutic platform for metabolic, neurologic, cancer, and infectious diseases [5] created to mirror the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker has demonstrated success against multiple disease categories including neurological, cancer, antiviral. [10] Linebacker has been licensed to Prophase Laboratories for down range development and distribution. [6]
A patented Over the Counter (OTC) medication successfully tested in vitro against Rhinovirus, Influenza, Cholera, SARS-CoV-2 (COVID-19) and in a Biosafety Level 4 facility, Ebola. Equivir/Nemovir is both a treatment and a prophylactic for COVID-19 and is moving to human clinical trials. [11] Equivir has been licensed to Prophase Laboratories for down range development and distribution. [6]
3F stands for “Functional Fragrance Formulation”. The 3F Biofragrance technologies is a suite of “functional fragrances” specifically designed for addition to consumer products such as cosmetics, detergents, and air fresheners to boost the products effectiveness or add additional protective properties. These properties include insect protection, antimicrobial, preservative, synergistic and healing capabilities.
The 3F Biofragrance is the product of a 3 year research project conducted on over 270 rare orchid scents from across the globe. The project yielded a vast library of compounds that cover wide variety of biological activities. These compounds, once cataloged and identified can be used to create unique and numerous bioactive formulas that mimic a pleasant smell. [12]
The 3F Antimicrobial formula has been tested and proven effective against a number of resistant pathogenic bacterial microorganisms such as E.coli, MRSA, Staph, C.albicans, Tuberculosis as well as numerous strains of problematic viruses including rhinovirus, influenza and SARS-COV2. [12]
3F Antimicrobial has proven to be synergistic with ethyl alcohol which translates into lower levels of alcohol required for formulation while also increasing the effectiveness against target microorganisms thus making a cleaner, safer and more effective sanitizer. [12]
The 3F DEET Booster is designed to work synergistically to increase effectiveness of insect repellency while also allowing for the reduction of DEET required within the formula. 3F DEET Booster improves overall protection and creates a superior product that has a pleasant and enjoyable scent with a much better feel to the skin. [12]
GRDG has done research to identify key compounds within the ghost orchid’s scent that have the ability to interact or block mosquito’s ability to detect humans as prey. They have since worked with these compounds to create functional scents that can block these receptors and make humans invisible to mosquitoes. [12]
A Sugar modification technology, designed as a solution to the growing global trend of Diabetes and Obesity. Our modified sugar is not only has 30% reduced carbohydrate but also actively reverse insulin resistance. Laetose solves the global Sugar and Salt Reduction Initiative. [13]
An improved form of the antihistamine Diphenhydramine with increased binding characteristics. Q-Diphen was designed specifically as a emerging SARS-COV2 prophylactic strategy. [14]
The solution to the Patent Cliff [15] accomplished by creating a new class of medicinal chemistry that uses advanced methods to increase effectiveness and persistence of natural compounds and existing drugs. The safety attributes of the original molecules are maintained. Typically, drug discovery processes modify functional groups. The Bioforge's new techniques alter the behavior of molecules at the sub-molecular level. GRDG estimates that 65% of the World Health Organization Essential Medicines List can be improved and re-patented using Bioforge and these methods can be used to enhance and patent natural compounds including many substances used in traditional medicines around the world. [16] [17]
GRDG is working on advanced bio-compatible plastics that mitigate accumulation of plastics in oceans and landfills and also provide UVA and UVB protection for many types of material for including containers, hard surfaces, and fibers for clothing. The technology is presently in development and testing.
The bioplastics will have contain antimicrobial properties for consumer products that control the spread of active pathogens such as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus, by exploiting key strategies found in the biological realm. These new plastics are specifically focused on solutions for common products such as cups, plates, utensils, plastic bags, and countertops. The first prototypes are currently undergoing antimicrobial resistance testing. [18]
Thompson has successfully developed, patented, and/or marketed:
The Grapefruit Solution: Lower Your Cholesterol, Lose Weight and Achieve Optimal Health with Nature’s Wonder Fruit (LINX Corp., 2004), with M. Joseph Ahrens [30]
Endocrinology is a branch of biology and medicine dealing with the endocrine system, its diseases, and its specific secretions known as hormones. It is also concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Specializations include behavioral endocrinology and comparative endocrinology.
Insulin is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the insulin (INS) gene. It is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood into liver, fat and skeletal muscle cells. In these tissues the absorbed glucose is converted into either glycogen via glycogenesis or fats (triglycerides) via lipogenesis, or, in the case of the liver, into both. Glucose production and secretion by the liver is strongly inhibited by high concentrations of insulin in the blood. Circulating insulin also affects the synthesis of proteins in a wide variety of tissues. It is therefore an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood have the opposite effect by promoting widespread catabolism, especially of reserve body fat.
Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).
Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/L (200 mg/dL), but symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/L (~250–300 mg/dL). A subject with a consistent fasting blood glucose range between ~5.6 and ~7 mmol/L is considered slightly hyperglycemic, and above 7 mmol/L is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dL) can produce noticeable organ damage over time.
In cellular biology, active transport is the movement of molecules or ions across a cell membrane from a region of lower concentration to a region of higher concentration—against the concentration gradient. Active transport requires cellular energy to achieve this movement. There are two types of active transport: primary active transport that uses adenosine triphosphate (ATP), and secondary active transport that uses an electrochemical gradient. This process is in contrast to passive transport, which allows molecules or ions to move down their concentration gradient, from an area of high concentration to an area of low concentration, without energy.
A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The blood sugar level, blood sugar concentration, blood glucose level, or glycemia is the measure of glucose concentrated in the blood. The body tightly regulates blood glucose levels as a part of metabolic homeostasis.
Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes. It may be used with metformin, a sulfonylurea, or insulin. Use is recommended together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.
Bromocriptine, originally marketed as Parlodel and subsequently under many brand names, is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes.
Sulfonylureas or sulphonylureas are a class of organic compounds used in medicine and agriculture. The functional group consists of a sulfonyl group (-S(=O)2) with its sulphur atom bonded to a nitrogen atom of a ureylene group (N,N-dehydrourea, a dehydrogenated derivative of urea). The side chains R1 and R2 distinguish various sulfonylureas. Sulfonylureas are the most widely used herbicide.
Rasagiline is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Eva Lucille Feldman is an American physician-scientist who is a leading authority on neurodegenerative disease. She serves as the Russell N. DeJong Professor of Neurology at the University of Michigan, as well as Director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also named the James W. Albers Distinguished University Professor of Neurology.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.
PPAR agonists are drugs which act upon the peroxisome proliferator-activated receptor. They are used for the treatment of symptoms of the metabolic syndrome, mainly for lowering triglycerides and blood sugar.
Michael Cowley FTSE is an Australian physiologist. He is best known for his mapping of the neural circuits involved in metabolism and obesity and diabetes treatment. He is a professor in the Department of Physiology at Monash University in the Faculty of Biomedical and Psychological Sciences. He is also a director of the Australian diabetes drug development company, Verva Inc, and director of the Monash Obesity & Diabetes Institute] (modi).
M. Joseph Ahrens is an American entrepreneur, scientist, and inventor whose work focuses on research, product development, business development, and operations in agriculture and food industries.
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year.
Mark L. Nelson is an American chemist specializing in the field of antibiotics and tetracyclines. His synthesis techniques have resulted in over 40 patents and he conceived and synthesized with Mohamed Ismail along with Laura Honeyman, the tetracycline antibiotic Omadacycline (Nuzyra), the first of the Aminomethylcycline subclass of tetracyclines to reach medical use. Nuzyra is useful against resistant bacteria and used for severe cases of skin infections, ABSSSIs, Community Acquired Pneumonia (CABP) and nontuberculosis mycobacteria. Nuzyra also has demonstrated activity against Anthrax, and was purchased by the US government under a BARDA contract for Project Bio-shield to treat anthrax exposure, and is now in the Strategic National Stockpile in the US in case of a bioterrorism attack. Nuzyra was also approved for use against the Plague, caused by Yersinia pestis infections.
Glysobuzole is an oral antidiabetic drug, it is taken once daily by oral administration and it is water soluble to become pharmaceutically active within the gastrointestinal tract. It is a sulfonamide derivative that is similar to sulfonylureas. Glysobuzole has antihyperglycemic activity, so it is able to lower blood glucose levels by increasing the release of insulin from the pancreatic beta cells. Glysobuzole functions as a modulator in metabolic processes involving insulin and therefore it is used to treat diabetes.
{{cite press release}}: |last= has generic name (help)